MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

2.96 0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.92

Max

3.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.59% upside

Dividenden

By Dow Jones

Volgende Winsten

11 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-62M

1.1B

Vorige openingsprijs

2.62

Vorige sluitingsprijs

2.96

Nieuwssentiment

By Acuity

50%

50%

170 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 apr 2026, 23:17 UTC

Winsten

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Populaire aandelen

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

Belangrijke Marktbewegers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisities, Fusies, Overnames

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

Belangrijke Marktbewegers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

Belangrijke Marktbewegers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Marktinformatie

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Marktinformatie

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Marktinformatie

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Marktinformatie

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Marktinformatie

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Marktinformatie

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Marktinformatie

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Winsten

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

35.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  35.59%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

170 / 349 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat